In order to help its clients face an increasingly complicated clinical trials regulatory environment, Epstein Becker & Green PC has created a team of legal, clinical and financial experts devoted specifically to solving clinical trials issues.
Monday’s landmark Supreme Court decision in KSR International Co. v. Teleflex Inc. will affect almost every unexpired patent and patent application. As the patent community struggles to understand and interpret this new precedent, ripples of change will be felt from the Federal Circuit down.
A district judge threw out the lawsuit of an infertile woman on Friday, saying she lacked evidence that her mother took the Eli Lilly and Co. miscarriage prevention drug that she alleged caused her condition.
An administrative law judge has recommended that the U.S. Securities and Exchange Commission suspend or revoke the registration of Impax Laboratories on the grounds that the pharmaceutical company has not filed a financial report since 2004.
Pennsylvania’s two largest insurance companies have formally requested that the Pennsylvania Department of Insurance review their proposed $120 million merger to ensure that the deal does not violate antitrust statutes.
A Canadian appeals court has upheld patents for painkiller Celebrex that prevent the launch of a generic version of the drug until November 2014, Pfizer Inc. said Tuesday.
The White House on Tuesday expressed firm opposition to any attempt to add a law that would pave the way for generic or follow-on drugs to be approved to a bill allowing the Food and Drug Administration to collect fees that is currently being debated in the U.S. Senate.
In a decision that could have far-reaching implications for the pharmaceutical industry, a U.S. district court judge has knocked down an unprecedented New Hampshire law that banned the commercial use of information on the drugs physicians prescribe.
An attempt by the Food and Drug Administration to block a subpoena sought by a small biotechnologies firm in a case brought by the U.S. Securities and Exchange Commission has failed, after a district court refused to grant the agency’s request for an injunction.
Bingham McCutchen LLP has pulled in a team of 40 lawyers after combining with high-stakes litigation firm Alschuler Grossman LLP in a move that will expand its key practice areas of intellectual property, securities and mergers and acquisitions.
The Supreme Court on Monday issued a much-anticipated ruling in the KSR International Co. v. Teleflex Inc. patent dispute, reversing the Federal Circuit’s decision that in turn reversed a district court ruling finding a Teleflex patent invalid due to obviousness.
A federal judge has denied and granted in part Synergetics Inc.’s request for more time to respond to Peregrine Surgical Ltd.’s summary judgment motion in a patent infringement case over membrane erasers used in ophthalmic surgery.
The U.S. Food and Drug Administration has rejected Merck & Co.’s bid for approval of its painkiller and osteoarthritis treatment Arcoxia, a drug that is in the same class as Vioxx, over which the company faces a slew of lawsuits.
Trademark owners cannot bar companies from reselling trademarked medicines as long as the packaging of such products conforms to certain conditions, Europe’s highest court has ruled.
Industry representatives, patent attorneys and advocates have praised lawmakers for their attempt to overhaul U.S. patent law, but also urged them to be careful of measures that may weaken protections for certain inventors.
The leading artificial teeth supplier in the country, Dentsply International Inc., was hit with an antitrust suit on Wednesday for allegedly monopolizing the market for artificial teeth.
Brazil on Wednesday reportedly threatened to break Merck & Co. Inc.’s patent on HIV/AIDS drug Efavirenz, warning it will tap into India’s generic drug industry if the pharmaceutical giant will not offer the country a lower price for the much-needed medicine.
A judge has amended the terms of a $63.8 million nationwide class action settlement reached in 2006 by drug maker GlaxoSmithKline, allocating more of the massive sum to consumers.
A medical device maker has resolved long-standing patent litigation with Royal Philips Electronics NV over cardiac defibrillator technology and plans to pay $1 million for a license to Philips’ other patents.
The European Parliament on Wednesday voted in favor of establishing EU-wide rules to regulate new gene, cell and tissue therapies, in an effort to ensure product safety and to foster cross-border competition.